IDXXMEDIUM SIGNALFINANCIAL10-K

IDEXX significantly increased share buybacks to $1.2B while strengthening operations with 20.5% operating income growth, though cash reserves declined substantially.

The company is aggressively returning capital to shareholders through increased buybacks while maintaining strong operational performance with double-digit revenue and profit growth. However, the 37.5% decline in cash reserves to $180M may limit future financial flexibility, though debt reduction of $167M partially offsets this concern.

Comparing 2026-02-20 vs 2025-02-21View on EDGAR →
FINANCIAL ANALYSIS

IDEXX delivered robust operational performance with revenue growing 10.4% to $4.3B and operating income surging 20.5% to $1.4B, demonstrating strong business fundamentals. The company significantly ramped up capital returns with share buybacks increasing 45.4% to $1.2B, funded by strong operating cash flow growth of 27.2% and debt reduction of $167M. While the 37.5% decline in cash to $180M reflects aggressive capital allocation, the overall picture signals a financially healthy company confidently investing in growth (R&D up 14.3%) while aggressively returning excess capital to shareholders.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
+45.4%
$837.0M→$1.2B

Share repurchases increased 45.4% — management returning capital, signals confidence in intrinsic value.

Cash & Equivalents
Balance Sheet
-37.5%
$288.3M→$180.1M

Cash declined 37.5% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Debt
Balance Sheet
-27.2%
$617.8M→$450.0M

Debt reduced 27.2% — deleveraging strengthens balance sheet and reduces financial risk.

Operating Cash Flow
Cash Flow
+27.2%
$929.0M→$1.2B

Operating cash flow grew 27.2% — strong conversion of earnings to cash, healthy business fundamentals.

Operating Income
P&L
+20.5%
$1.1B→$1.4B

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Net Income
P&L
+19.3%
$887.9M→$1.1B

Net income grew 19.3% — bottom-line growth signals improving overall business health.

Accounts Receivable
Balance Sheet
+16.6%
$473.6M→$552.4M

Receivables grew 16.6% — monitor days sales outstanding for collection efficiency.

R&D Expense
P&L
+14.3%
$219.8M→$251.2M

R&D investment increased 14.3% — signals commitment to future product development, though near-term margin impact.

Gross Profit
P&L
+11.8%
$2.4B→$2.7B

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Revenue
P&L
+10.4%
$3.9B→$4.3B

Revenue growing 10.4% — solid top-line momentum, watch margins for quality of growth.

LANGUAGE CHANGES
NEW — 2026-02-20
PRIOR — 2025-02-21
ADDED
Credit Facility Our $1.25 billion five-year unsecured credit facility under our fourth amended and restated credit agreement, as amended; consisting of i) $1 billion revolving credit facility, also referred to as the revolving line of credit, ii) $250 million three-year term loan facility and iii) flexibility to incur incremental revolving credit commitments and/or term loans in the aggregate principal amount of up to $250 million.
Reagent rentals Instruments being placed at customer sites at little or no cost in exchange for a long-term customer commitment to purchase instrument consumables.
Term Loan Three year, unsecured term loan in the principal amount of $250 million under the Credit Facility S P Standard Poor s S P 500 Health Care Index The index for the S P 500 Health Care (U.S.
IDEXX TM and other trademarks appearing in this report are registered trademarks or trademarks of IDEXX and its affiliates in the United States and other countries, except for VetAutoread, which is a trademark of QBC Diagnostics, and SimPlate, which is a trademark of Merck KGaA or its affiliates.
Solely for convenience, trademarks, trade names and service marks referred to in this Annual Report on Form 10-K may appear without the , or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights to these trademarks, trade names and service marks.
+7 more — sign up free →
REMOVED
cGMP The FDA s current Good Manufacturing Practice regulations.
Credit Facility Our $1.25 billion five-year unsecured credit facility under an amended and restated credit agreement; consisting of i) $1 billion revolving credit facility, also referred to as line of credit, and ii) $250 million three-year term loan.
OPTI Medical OPTI Medical Systems, Inc., a wholly-owned subsidiary of IDEXX Laboratories Inc., located in Roswell, Georgia.
This business provides point-of-care and laboratory diagnostics (including electrolyte and blood gas analyzers and related consumable products) for the human medical diagnostics sector.
The Roswell facility also manufactures electrolytes slides (instrument consumables) to run Catalyst One , Catalyst Dx , and blood gas analyzers and consumables for the veterinary market; also referred to as OPTI.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →